ArticleFrontiers in pharmacology2025
Oxytropis falcata bunge extract combined with black soybean oil ameliorates DNCB-induced atopic dermatitis-like skin inflammation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: To investigate the anti-inflammatory effects and underlying mechanisms of Methods: Mice were divided into six groups: positive control (1% mometasone furoate), OFE, BSO, OFE + BSO, DNCB, and control. After 20 days of local application of each ointment, therapeutic effects were evaluated. Histopathological examination was performed to assess skin thickness and mast cell infiltration. ELISA was used to quantify proinflammatory cytokines, real-time PCR measured IL-36 mRNA levels, and Western blotting analyzed HDAC3/NF-κB and CysLTR1 protein expression. Results: All treatments alleviated DNCB-induced atopic dermatitis symptoms, with the combination group showing the most significant improvement in epidermal thickness, mast cell infiltration, and dermatitis severity. In addition, the treatment groups suppressed activation of the HDAC3/NF-κB signaling pathway. Conclusion: The combination of OFE and BSO can effectively reduce DNCB-induced atopic dermatitis in mice. Its action does not rely on broad immunosuppression or induce skin toxicity and may involve inhibition of proinflammatory cytokine release and downregulation of the HDAC3/NF-κB signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.